GenMark Diagnostics (GNMK) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Needham & Company Reiterates a Buy Rating as GenMark Diagnostics (GNMK) Reports 4Q Results Consistent with Preannouncement
February 24, 2016 10:36 AM ESTNeedham & Company maintained a Buy rating on GenMark Diagnostics (NASDAQ: GNMK), and cut the price target to $11.00 (from $13.00), following the company's 4Q earnings report. Revenue was $13.2M vs. consensus of $8.2M and GAAP EPS was ($0.21) vs. consensus of ($0.27). GNMK guided to 2016 revenue of... More
